📊 LNSR Key Takeaways
Is LENSAR, Inc. (LNSR) a Good Investment?
LENSAR exhibits a critical disconnect between reported net income ($36.3M) and negative operating cash flow (-$4.3M), indicating the majority of profits stem from non-operating items rather than core business operations. The company is burning cash while showing negative FCF margin (-32.4%), suggesting the current earnings quality is unsustainable for a medical device manufacturer with only $13.4M quarterly revenue.
Despite 13% revenue growth, LENSAR remains deeply unprofitable with a -42% operating margin, -59% net margin, and -25.5% FCF margin. Negative stockholders’ equity, weak liquidity (quick 0.62x), and negative interest coverage indicate balance-sheet stress and a likely need for external financing. Until margins and cash burn improve meaningfully, the risk profile outweighs the growth.
LENSAR, Inc. Key Strengths (LNSR)
- Revenue growth of 13.1% YoY demonstrates market traction
- Positive operating income ($2.2M) and operating margin (16.7%) in core business
- No long-term debt and current ratio of 2.38x provide balance sheet stability
- Double-digit revenue growth (+13.1% YoY)
- Low capital intensity (capex ~$0.08M)
- Current ratio above 1.0x offers limited near-term flexibility
LNSR Stock Risks: LENSAR, Inc. Investment Risks
- Operating cash flow is negative (-$4.3M) while company reports large net income, indicating non-operating gains distorting profitability
- Free cash flow is -$4.4M with -32.4% FCF margin, revealing business is not self-sustaining on cash basis
- Gap of $34.1M between operating income ($2.2M) and net income ($36.3M) suggests reliance on one-time items, likely unsustainable
- Weak interest coverage ratio (1.7x) limits financial flexibility
- Small revenue base ($13.4M) for medical device sector with uncertain path to cash profitability
- Negative equity and weak liquidity suggest going-concern risk
- Persistent losses and negative FCF imply dilution/financing needs
- Negative interest coverage indicates inability to service obligations without improvement
Key Metrics to Watch
- Operating cash flow trend - critical indicator of true profitability
- Composition and sustainability of non-operating income driving net income
- Free cash flow and cash runway given current burn rate
- Operating cash flow and cash runway
- Operating margin trajectory toward break-even
LENSAR, Inc. (LNSR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.38x current ratio provides a solid financial cushion.
LNSR Profit Margin, ROE & Profitability Analysis
LNSR vs Healthcare Sector: How LENSAR, Inc. Compares
How LENSAR, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LENSAR, Inc. Stock Overvalued? LNSR Valuation Analysis 2026
Based on fundamental analysis, LENSAR, Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LENSAR, Inc. Balance Sheet: LNSR Debt, Cash & Liquidity
LNSR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: LENSAR, Inc.'s revenue has grown significantly by 75% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.73 indicates the company is currently unprofitable.
LNSR Revenue Growth, EPS Growth & YoY Performance
LNSR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $11.7M | -$27.3M | $0.00 |
| Q3 2025 | $11.8M | -$1.5M | $-0.13 |
| Q2 2025 | $10.7M | -$1.8M | $-0.15 |
| Q1 2025 | $8.6M | -$2.2M | $-0.19 |
| Q3 2024 | $8.3M | -$1.5M | $-0.13 |
| Q2 2024 | $10.3M | -$2.2M | $-0.79 |
| Q1 2024 | $6.6M | -$2.2M | $-0.19 |
| Q3 2023 | $6.3M | $2.6M | $-0.23 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
LENSAR, Inc. Dividends, Buybacks & Capital Allocation
LNSR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for LENSAR, Inc. (CIK: 0001320350)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LNSR
What is the AI rating for LNSR?
LENSAR, Inc. (LNSR) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 77% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LNSR's key strengths?
Claude: Revenue growth of 13.1% YoY demonstrates market traction. Positive operating income ($2.2M) and operating margin (16.7%) in core business. ChatGPT: Double-digit revenue growth (+13.1% YoY). Low capital intensity (capex ~$0.08M).
What are the risks of investing in LNSR?
Claude: Operating cash flow is negative (-$4.3M) while company reports large net income, indicating non-operating gains distorting profitability. Free cash flow is -$4.4M with -32.4% FCF margin, revealing business is not self-sustaining on cash basis. ChatGPT: Negative equity and weak liquidity suggest going-concern risk. Persistent losses and negative FCF imply dilution/financing needs.
What is LNSR's revenue and growth?
LENSAR, Inc. reported revenue of $13.4M.
Does LNSR pay dividends?
LENSAR, Inc. does not currently pay dividends.
Where can I find LNSR SEC filings?
Official SEC filings for LENSAR, Inc. (CIK: 0001320350) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LNSR's EPS?
LENSAR, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is LNSR's fundamental grade?
Based on our AI fundamental analysis in May 2026, LENSAR, Inc. has a C grade with 77% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is LNSR stock overvalued or undervalued?
Valuation metrics for LNSR: ROE of 336.7% (sector avg: 15%), net margin of 270.6% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
What is LNSR's AI grade for 2026?
Our dual AI analysis gives LENSAR, Inc. a combined C grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is LNSR's free cash flow?
LENSAR, Inc.'s operating cash flow is $-4.3M, with capital expenditures of $83.0K. FCF margin is -32.4%.
How does LNSR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 270.6% (avg: 12%), ROE 336.7% (avg: 15%), current ratio 2.38 (avg: 2).
Why is LNSR's return on equity (ROE) so high?
LENSAR, Inc. has a return on equity of 336.7%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 270.6% net margin.